BTK Inhibitors and Managing Adverse Events

What are BTK inhibitors and how do they work in chronic lymphocytic leukemia (CLL)? Kerry A. Rogers, MD, assistant professor of Medicine, Division of Hematology at The Ohio State University Comprehensive Cancer Center – The James, joins Patient Power to explain the commonality of certain adverse events when treating CLL with BTK inhibitors and whether adverse events can be predicted.

Support for this series has been provided by AstraZeneca Oncology. Patient Power maintains complete editorial control and is solely responsible for program content.

© 2024 HealthCentral LLC. All rights reserved.

More Videos